Clinical Response Is a Meaningful Endpoint in Ulcerative Colitis Clinical Studies
William J. Sandborn(University of San Diego), Paul Rutgeerts(KU Leuven), Brian Feagan, Peter G. Gibson(University Gastroenterology), Gunnar Järnerot(Örebro University Hospital), Colleen Marano(Johnson & Johnson (United States)), Cynthia Guzzo(Janssen (Belgium)), Hongyan Zhang(Tianjin University), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Judith Collins(Oregon Health & Science University), Richard Strauß(Hennepin County Medical Center), Jewel Johanns(Johnson & Johnson (United States)), Walter Reinisch(Medical University of Vienna)
Cited by 3
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k